COVID-19 pandemic response
In keeping with government guidelines we re-opened our buildings for lab-based research on 11th June, but with greatly reduced staff numbers. Stringent new measures are in place to ensure that we can operate safely.
We continue to work from home wherever this is possible so please contact us by email.
About us
The Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories (IMS-MRL) and its embedded MRC Metabolic Diseases Unit investigate the mechanisms through which metabolic health is maintained and how this is disturbed in disease.
We seek to use that knowledge to aid better treatment and prevention of obesity, Type 2 diabetes and related endocrine and metabolic diseases.
IMS-MRL groups encompass skills in genetics, cell biology, cell signalling, neuroendocrinology, bioenergetics, human and animal physiology, experimental medicine and clinical trials.
The IMS-MRL is the base for the MRC Metabolic Diseases Unit which supports four programmes of research that aim to improve understanding of the mechanisms responsible for obesity and related metabolic diseases.
Together with a Welcome Strategic Award, it also supports core scientific facilities that underpin basic and experimental science at the IMS-MRL.
Videos
News
Stress does not lead to loss of self-control in eating disorders
In a study carried out at the Wellcome-MRC Institute of Metabolic Science (IMS) Translational Research Facility (TRF) in Cambridge,women with eating disorders were assessed…
Continue Reading Stress does not lead to loss of self-control in eating disorders
MC4R regulates body weight through multiple cellular mechanisms
The brain expressed Melanocortin 4 receptor (MC4R) plays a critical role in regulating appetite and weight. Geneticvariants in MC4R represent the commonest monogenic…
Continue Reading MC4R regulates body weight through multiple cellular mechanisms
Setmelanotide approved by the FDA for treatment of genetic obesity syndromes
Rhythm Pharmaceuticals has just announced that the US Food and Drug Administration (FDA) has approved the MC4R agonist, IMCIVREE™ (setmelanotide) for chronic weight management…
Continue Reading Setmelanotide approved by the FDA for treatment of genetic obesity syndromes
Dr Hisham Ziauddeen – RCPsych 2020 Psychiatric Communicator of the Year
Congratulations to Dr Hisham Ziauddeen on being announced as Psychiatric Communicator of the Year in the Royal College of Psychiatrists’ Annual Awards. Hisham is…
Continue Reading Dr Hisham Ziauddeen – RCPsych 2020 Psychiatric Communicator of the Year
